We are live on
!
Find out more
Mirae Asset Global Investments Portfolio holdings
AUM
$67.7B
1-Year Est. Return
57.61%
This Fund
S&P 500
This Quarter
Est. Return
+4.4%
1 Year Est. Return
+57.61%
3 Year Est. Return
+150.9%
5 Year Est. Return
+201.56%
10 Year Est. Return
+1,018.7%
AUM
$24.6B
AUM Growth
+$2.03B
(+9%)
Cap. Flow
+$1.28B
Cap. Flow
% of AUM
5.2%
Top 10 Holdings %
Top 10 Hldgs %
38.38%
Holding
1,702
New
151
Increased
731
Reduced
674
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$167M |
| 2 |
Apple
AAPL
|
+$66M |
| 3 |
Microsoft
MSFT
|
+$57.3M |
| 4 |
HDFC Bank
HDB
|
+$44M |
| 5 |
Schwab US Dividend Equity ETF
SCHD
|
+$41.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$81.5M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$81.3M |
| 3 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$45.8M |
| 4 |
Advanced Micro Devices
AMD
|
+$43.4M |
| 5 |
Meta Platforms (Facebook)
META
|
+$35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.15% |
| 2 | Consumer Discretionary | 10.25% |
| 3 | Communication Services | 8.94% |
| 4 | Healthcare | 6.61% |
| 5 | Financials | 5.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1526
C4 Therapeutics
CCCC
$506M
| $8.91K | ﹤0.01% |
+2,352
| New | +$11.7K |
|
|
ITOS
1527
DELISTED
iTeos Therapeutics
ITOS
| $8.91K | ﹤0.01% |
1,217
-104
| -8% | -$894 |
|
1528
Amylyx Pharmaceuticals
AMLX
$2.54B
| $8.84K | ﹤0.01% |
2,284
-178
| -7% | -$838 |
|
|
ARTV
1529
Artiva Biotherapeutics
ARTV
$557M
| $8.61K | ﹤0.01% |
+809
| New | +$9.72K |
|
1530
Flywire
FLYW
$2.15B
| $8.58K | ﹤0.01% |
416
-84
| -17% | -$1.64K |
|
1531
4D Molecular Therapeutics
FDMT
$607M
| $8.55K | ﹤0.01% |
1,540
-340
| -18% | -$2.67K |
|
1532
Larimar Therapeutics
LRMR
$444M
| $8.42K | ﹤0.01% |
+2,126
| New | +$14K |
|
1533
StoneCo
STNE
$2.5B
| $7.79K | ﹤0.01% |
977
-198
| -17% | -$2.01K |
|
1534
Lexeo Therapeutics
LXEO
$407M
| $7.47K | ﹤0.01% |
+1,102
| New | +$8.68K |
|
|
IGMS
1535
DELISTED
IGM Biosciences
IGMS
| $7.24K | ﹤0.01% |
+1,136
| New | +$13.5K |
|
1536
Inhibrx
INBX
$1.47B
| $7.24K | ﹤0.01% |
+482
| New | +$7.34K |
|
1537
Precigen
PGEN
$2.33B
| $7.09K | ﹤0.01% |
9,759
-647
| -6% | -$552 |
|
|
CMPS
1538
Compass Pathways
CMPS
$1.89B
| $6.76K | ﹤0.01% |
+1,694
| New | +$8.59K |
|
1539
MacroGenics
MGNX
$263M
| $6.75K | ﹤0.01% |
2,091
-178
| -8% | -$641 |
|
1540
dLocal
DLO
$4.31B
| $6.49K | ﹤0.01% |
576
-91
| -14% | -$916 |
|
|
INZY
1541
DELISTED
Inozyme Pharma
INZY
| $6.25K | ﹤0.01% |
+2,141
| New | +$8.14K |
|
|
HAPN
1542
Happen Inc
HAPN
$2.28B
| $6.2K | ﹤0.01% |
383
-78
| -17% | -$1.15K |
|
|
MRSN
1543
DELISTED
Mersana Therapeutics
MRSN
| $6.18K | ﹤0.01% |
+165
| New | +$8.54K |
|
1544
Acrivon Therapeutics
ACRV
$78.3M
| $6.14K | ﹤0.01% |
+1,038
| New | +$7.54K |
|
1545
Fate Therapeutics
FATE
$311M
| $6.11K | ﹤0.01% |
+3,795
| New | +$9.56K |
|
|
EQC
1546
DELISTED
Equity Commonwealth
EQC
| $6.11K | ﹤0.01% |
3,490
-675
| -16% | -$10.4K |
|
1547
Lyell Immunopharma
LYEL
$343M
| $6.05K | ﹤0.01% |
465
+2
| +0.4% | +$40 |
|
1548
Tevogen Inc. Common Stock
TVGN
$27.2M
| $6.01K | ﹤0.01% |
+117
| New | +$7.62K |
|
|
AMRN
1549
Amarin Corp
AMRN
$300M
| $5.97K | ﹤0.01% |
667
-57
| -8% | -$610 |
|
1550
Alector
ALEC
$232M
| $5.81K | ﹤0.01% |
3,263
-257
| -7% | -$967 |
|
Similar funds
Mirae Asset Global Investments's Q4 2024 Portfolio in Review
As of Q4 2024, Mirae Asset Global Investments held 1,702 positions worth $24.6B, up 9% from $22.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Mirae Asset Global Investments deployed $1.28B of net new capital in Q4 2024, opening 151 new positions and adding to 731 existing holdings. Its largest new stake was Strategy Inc: 36,162 shares worth $11.8M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $81.5M trimmed.
- Mirae Asset Global Investments's largest Q4 2024 buy was Strategy Inc: 36,162 shares worth $11.8M.
- Mirae Asset Global Investments added most to Vanguard S&P 500 ETF in Q4 2024, an estimated $167M increase.
- Mirae Asset Global Investments's biggest Q4 2024 reduction was Invesco QQQ Trust, cutting an estimated $81.5M.
- Mirae Asset Global Investments fully exited VanEck Pharmaceutical ETF in Q4 2024, selling an estimated $23.6M.
- Mirae Asset Global Investments's ten largest holdings make up 38% of its $24.6B portfolio in Q4 2024.
- Mirae Asset Global Investments opened 151 new positions and closed 110 in Q4 2024.
- Mirae Asset Global Investments's portfolio value rose 9% quarter-over-quarter to $24.6B.
Based on Mirae Asset Global Investments's 13F filing for Q4 2024, filed 27 Jan 2025.